Back to today’s briefing

Story perspectives

Breakthrough ALS Therapies Ignite Hope for Patients

5/5/2025

50 10

Summary

Story summary

Exciting breakthroughs in gene and RNA-targeted therapies for amyotrophic lateral sclerosis (ALS) are on the horizon. The FDA's 2023 approval of tofersen for SOD1-mutated ALS marks a significant step in slowing disease progression. With new therapies targeting various proteins and vital biomarkers like neurofilament light chain (NfL) for personalized care, hope is rising for those affected by this devastating condition.

1 of 1

Story summary

Exciting breakthroughs in gene and RNA-targeted therapies for amyotrophic lateral sclerosis (ALS) are on the horizon. The FDA's 2023 approval of tofersen for SOD1-mutated ALS marks a significant step in slowing disease progression. With new therapies targeting various proteins and vital biomarkers like neurofilament light chain (NfL) for personalized care, hope is rising for those affected by this devastating condition.